Wegovy Weight Loss by Week: Full Timeline

Introduction

Wegovy® is semaglutide 2.4 mg dosed once weekly for chronic weight management. The phase 3 STEP 1 trial (Wilding et al. 2021 NEJM) ran for 68 weeks and produced a mean weight loss of 14.9% on the active arm. The week-by-week curve from that trial is the cleanest data we have.

Real-world patients tend to track close to the trial curve when adherence is good and the dose ramp is followed. Slower titration produces a slower early curve. Skipping doses produces a flatter overall trajectory.

This timeline walks through week-by-week expectations using STEP 1 data and standard dose ramping protocols. Individual results vary. Top responders lose nearly twice the mean. Partial responders lose much less.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s the Standard Wegovy Dose Ramp?

The label-approved Wegovy titration runs 16 weeks before you hit the full 2.4 mg maintenance dose. Weeks 1-4 are 0.25 mg, weeks 5-8 are 0.5 mg, weeks 9-12 are 1.0 mg, weeks 13-16 are 1.7 mg, and week 17 onward is 2.4 mg.

Quick Answer: STEP 1 (Wilding et al. 2021 NEJM) reported mean 14.9% body weight loss at 68 weeks

This slow ramp exists because of GI side effects. Nausea, constipation, and reflux peak in the first few weeks at each new dose level. Going slower reduces severity but extends the time before peak appetite suppression kicks in.

Some patients tolerate the ramp without issues. Others get stuck at 1.0 mg or 1.7 mg because of nausea and never reach 2.4 mg. In STEP 1, about 7% of patients stopped because of GI side effects.

Most weight loss in months 1-3 is driven by appetite reduction rather than the full pharmacological dose, which is why patients on lower titration doses still see meaningful loss.

Weeks 1-4: What Happens on 0.25 Mg?

Mean weight loss in STEP 1 by week 4 was roughly 1.5-2% of starting body weight. For a 250 lb starting weight, that’s 4-5 lb.

The 0.25 mg starting dose is mostly a tolerance dose. It’s not high enough to produce major appetite suppression in most people. The loss in weeks 1-4 comes from mild appetite changes and reduced water retention as eating patterns shift.

Side effects in this window are typically mild. Nausea is the most common. Constipation and fatigue show up in some patients. Most resolve within 7-10 days at the dose level.

If you’re not losing anything in weeks 1-4, that’s not a treatment failure. The real dose curve starts to show effects from week 5 onward.

Weeks 5-12: What’s the Dose-up Phase Look Like?

By week 12, STEP 1 patients averaged about 6% body weight loss. The 0.5 mg and 1.0 mg doses are where appetite suppression starts becoming clearly noticeable.

For a 250 lb starting weight, week 12 lands around 235 lb (15 lb down). For a 200 lb starting weight, week 12 lands around 188 lb (12 lb down).

Side effects can flare each time the dose increases. Some patients spend the first week of each new dose with mild nausea, then it fades. Others have rougher dose jumps.

This is also the window where patients most commonly stop. Almost half of all GLP-1 discontinuations happen in the first 12 weeks. Pushing through this period is the single biggest determinant of long-term results.

Weeks 13-20: Hitting the Full 2.4 Mg Dose

Most patients reach 2.4 mg at week 17. By week 20, STEP 1 mean cumulative loss was around 9-10% body weight.

Once on the maintenance dose, weight loss rate is at its highest. The full 2.4 mg produces the strongest appetite suppression, and the calorie deficit it creates is still large because body weight hasn’t dropped much yet.

Expect 1-2 lb per week in this window for most patients. Some lose faster (3-4 lb per week), some slower (0.5-1 lb per week). Personal variation is wide.

If you can’t tolerate 2.4 mg, staying at 1.7 mg long-term is a reasonable option. You’ll lose somewhat less but still meaningfully more than placebo.

Weeks 20-32: The Peak Fat-loss Zone

Between weeks 20-32, STEP 1 patients moved from about 10% loss to about 13% loss. This is when most of the year-one fat loss happens.

The loss rate is highest here because you’re at peak dose with the largest residual deficit. For most patients this is the period when clothes fit dramatically differently and the visible body change happens.

Adding resistance training during this window protects lean mass. Cardio is fine but doesn’t substitute for resistance work. The metabolic rate you preserve here matters for whether you keep weight off later.

Side effects typically stabilize by this point. Most patients tolerate 2.4 mg without ongoing GI issues by month 5-6.

Weeks 32-52: When the Curve Starts Flattening

By week 52, STEP 1 cumulative loss was around 14%. The slope from week 32 to week 52 is less steep than the slope from week 20 to week 32.

Three things are happening. Metabolic rate has dropped with body weight. The body has adapted somewhat to the appetite signaling. And the absolute deficit has shrunk because your body is smaller.

Patients who plateau early often do so in this window. If you’ve been losing at 1 lb per week and suddenly stop for 4 weeks, that’s worth looking at: dose, tracking, sleep, alcohol intake.

For most patients, this is also the window where the goal-weight question becomes real. Some patients are already at their target. Others want another 20-40 lb and need to decide how to push past the slowdown.

Key Takeaway: Most patients lose 5-7% by week 16 and 10% by week 32

Weeks 52-68: Maintenance Approach

STEP 1 ran 68 weeks total and the trial reported 14.9% mean cumulative loss at endpoint. Between weeks 52 and 68, the average patient lost another 1% of body weight.

This is the maintenance zone. Most patients on semaglutide 2.4 mg settle into a defended weight somewhere in this window. Continued small losses are possible but the rapid curve is over.

If you’re below your goal at week 68, the question becomes how to maintain. If you’re still above your goal, options include pushing food tracking tighter, adding exercise, or switching to tirzepatide (SURMOUNT-5 supports the molecule switch with a 6-7 percentage point advantage).

TrimRx offers compounded semaglutide for patients who want a more flexible cost structure than brand Wegovy, plus compounded tirzepatide for those considering a switch. The free assessment quiz can map dose and approach to your situation.

What Does the Curve Look Like Past 68 Weeks?

STEP 5 (Garvey et al. 2022 Nature Medicine) extended semaglutide treatment to 104 weeks and reported 15.2% mean loss at two years. Beyond 68 weeks, additional loss is small (0-2%) and the curve is essentially flat.

This is the practical ceiling for most patients on semaglutide 2.4 mg. Maintaining the loss is the work, not chasing more loss.

STEP 4 (Rubino et al. 2021 JAMA) showed what happens if you stop: two-thirds of lost weight comes back within a year. Continued dosing is what holds the loss.

If you’ve maxed out on semaglutide and want more loss, tirzepatide is the next-line option with the strongest published evidence.

What If Your Timeline Is Slower Than the Trial Curve?

Real-world patients commonly lag the trial curve by 2-4 percentage points at any given week. The reasons are slower titration, missed doses, weaker lifestyle adherence, and supply gaps.

If you’re at 4% loss by week 16 instead of 6%, you’re not failing. You’re in the lower half of the response distribution but still on a real trajectory.

If you’re at 0-1% by week 16 on a stable dose, you’re a likely partial responder. Talk to your provider about pushing the dose, checking adherence, or considering a switch.

The 12-week early-response check is the cleanest practical test. Real-world data shows early responders predict late responders.

How Does Wegovy Compare to Compounded Semaglutide Week-by-week?

Pharmacologically they’re the same molecule at the same effective dose. Compounded semaglutide from a licensed 503A or 503B compounding pharmacy uses identical active ingredient (semaglutide).

The week-by-week curve should match Wegovy when titration follows the same schedule and storage is appropriate. Studies haven’t directly compared the two, but the pharmacokinetic profile is determined by the molecule, not the manufacturer.

Differences in real-world experience come from titration flexibility, supply consistency, and program support. Brand Wegovy has insurance coverage in some plans. Compounded semaglutide is typically cash-pay and avoids supply issues that have hit branded products.

Bottom line: SELECT trial (Lincoff et al. 2023 NEJM) showed cardiovascular benefit at semaglutide 2.4 mg

FAQ

When Should I See Weight Loss Start on Wegovy?

Most patients see 2-4 lb of loss by week 4 on 0.25 mg. The strongest weekly loss rate typically hits between weeks 20 and 32 once you’re on the full 2.4 mg dose.

How Much Weight Will I Lose by 6 Months on Wegovy?

The STEP 1 trial average at week 28 was about 10-11% of body weight. For a 250 lb start, that’s 25-28 lb. Individual range is wide: top responders hit 15%+, partial responders are at 5-7%.

What’s the Average Wegovy Weight Loss at 1 Year?

STEP 1 reported 14.9% at 68 weeks. STEP 5 reported 15.2% at 104 weeks. The 12-month mark falls roughly between those, around 14-15% for most adherent patients.

Why Is My Weight Loss Slowing Down After 6 Months?

Metabolic rate drops with body weight, hunger adaptation partially offsets the drug, and behavior loosens. This is normal and matches the trial curve. Plateaus typically deepen in months 9-14.

Can I Stay on a Lower Wegovy Dose If 2.4 Mg Is Too Rough?

Yes. The 1.7 mg dose is approved as an alternative maintenance for patients who can’t tolerate 2.4 mg. Weight loss is somewhat less but still significant compared to placebo.

Will I Lose Weight Faster on Tirzepatide vs Wegovy?

On average yes. SURMOUNT-5 showed tirzepatide produced 20.2% vs semaglutide’s 13.7% at 72 weeks. Top responders on tirzepatide also went higher.

Does Taking Wegovy with Food Change the Weekly Result?

No. Semaglutide is injected subcutaneously and absorbed regardless of meal timing. The weekly dose curve is driven by injection schedule, not meal pattern.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.